机构：[1]Laboratory of Drug Metabolism & Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong, 510080, PR China[2]Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, 651 Dongfeng East Road, Guangzhou, Guangdong, 510080, PR China[3]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, Guangdong, 510080, PR China[4]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, PR China[5]Department of Pharmacy, Qingxi Hospital, Dongguan, Guangdong, 510080, PR China
Aim: To develop and validate a simple method using UPLC-MS/MS for determination of apatinib and its three active metabolites in a Phase IV clinical trial. Materials & methods: All compounds were separated on a Hypersil GOLD™ aQ C18 Polar Endcapped LC column (50 × 2.1 mm, 1.9 μm, Thermo) using 5 mmol/l ammonium acetate with 0.1% formic acid:acetonitrile (20:80, v/v) as the mobile phase after a rapid liquid-liquid extraction. This method was validated over the linear concentration range of 1.00-1000 ng/ml for each compound. Results: The interassay precision and accuracy were less than ±15%. The validated method was successfully applied to determine concentrations of clinical samples in non-small-cell lung cancer patients.
基金：
This study was funded by the National Science Foundation of China (grant nos. 81730103, 81320108027, 81573507,
81473283, 81173131 and 81973398), The National Key Research and Development Program (grant nos. 2017YFC0909303 and
2016YFC0905001), Guangdong Provincial Key Laboratory of Construction Foundation (grant no. 2017B030314030), National
Engineering and Technology Research Center for New drug Druggability Evaluation (Seed Program of Guangdong Province (grant
no. 2017B090903004), Science and Technology Planning Project of Guangdong Province, China (2014B020212014) and the 111
project (grant no: B16047).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|3 区生物
小类|3 区生化研究方法3 区分析化学
最新[2025]版：
大类|4 区医学
小类|4 区生化研究方法4 区分析化学
JCR分区：
出版当年[2017]版：
Q2BIOCHEMICAL RESEARCH METHODSQ2CHEMISTRY, ANALYTICAL
最新[2023]版：
Q3BIOCHEMICAL RESEARCH METHODSQ3CHEMISTRY, ANALYTICAL
第一作者机构：[1]Laboratory of Drug Metabolism & Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong, 510080, PR China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Shaoxing Guan,Wei Shi,Zerui Zhao,et al.Determination of apatinib and its three active metabolites by UPLC-MS/MS in a Phase IV clinical trial in NSCLC patients.[J].BIOANALYSIS.2019,11(22):2049-2060.doi:10.4155/bio-2019-0214.
APA：
Shaoxing Guan,Wei Shi,Zerui Zhao,Fei Wang,Fulin Jiang...&Xueding Wang.(2019).Determination of apatinib and its three active metabolites by UPLC-MS/MS in a Phase IV clinical trial in NSCLC patients..BIOANALYSIS,11,(22)
MLA：
Shaoxing Guan,et al."Determination of apatinib and its three active metabolites by UPLC-MS/MS in a Phase IV clinical trial in NSCLC patients.".BIOANALYSIS 11..22(2019):2049-2060
